(NASDAQ: HROW) Harrow's forecast annual revenue growth rate of 38.98% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 10.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.89%.
Harrow's revenue in 2026 is $275,594,000.On average, 11 Wall Street analysts forecast HROW's revenue for 2026 to be $13,410,153,702, with the lowest HROW revenue forecast at $12,527,689,713, and the highest HROW revenue forecast at $13,974,720,723. On average, 11 Wall Street analysts forecast HROW's revenue for 2027 to be $20,649,807,294, with the lowest HROW revenue forecast at $17,597,546,547, and the highest HROW revenue forecast at $23,612,846,958.
In 2028, HROW is forecast to generate $27,686,276,739 in revenue, with the lowest revenue forecast at $24,127,930,017 and the highest revenue forecast at $30,932,724,549.